New β-Lactam–β-Lactamase Inhibitor Combinations

2020/11/10 by Dafna Yahav, Christian G. Giske, Alise Grāmatniece +3 · 8 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Antibiotic Resistance in Bacteria #Antibiotics Pharmacokinetics and Efficacy #Pneumonia and Respiratory Infections

paper · doi:10.1128/cmr.00115-20

Abstract

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa .

Citations

• A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

Cited by

• Carbapenemases: epidemiology, detection and management in a changing global landscape
• Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review
• Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales
• Aztreonam–avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE)
• Pharmacophore-guided computational modeling of quinolone-ATPase conjugate inhibitors targeting DNA GyrB subunit of Staphylococcus aureus
• Cefepime‐taniborbactam: Ushering in the era of metallo‐β‐lactamase inhibition
• The challenges of difficult-to-treat <i>Acinetobacter</i> infections
• Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

Related

• Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review
• New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics
• Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline
• Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations
• Non- <i>Klebsiella pneumoniae</i> Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: <i>Burkholderia cepacia</i> Complex, <i>Stenotrophomonas maltophilia</i> , and <i>Acinetobacter baumannii</i>